ClinicalTrials.gg
Not yet recruitingNCT07503587PPFUpdated Mar 31, 2026

Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis

A Phase 3 interventional study of HSK44459 and Placebo in Progressive Pulmonary Fibrosis, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

02

Conditions studied

  • Progressive Pulmonary Fibrosis

Browse trials for

03

In context

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

This study's planned enrollment of 378 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.

Browse Pulmonary Fibrosis studies →

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged ≥18 year.
  2. Diagnosis of PPF other than IPF prior to screening or during the screening period.
  3. Patients must meet either of the following conditions:

1. not on therapy with nintedanib or pirfenidone for at least 8 weeks prior to screening and during the screening period, and not planning to start or restart antiibrotic therapy.

2.on stable therapy with nintedanib or pirfenidone for at least 12 weeks prior to screening and during the screening period.

4.Percentage Predicted Forced Vital Capacity (ppFVC) ≥45% at screening period. 5.Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for [Hb]) ≥ 25% and \<90% of predicted normal at screening period .

Exclusion criteria

Exclusion Criteria:

  1. airways obstruction ( (FEV1)/Forced Vital Capacity (FVC) \< 0.7) at screening.
  2. In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
  3. Acute ILD exacerbation within 3 months prior to screening and/or during the screening period.
  4. History of within 5 years prior to screening.
  5. History of vasculitis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
378 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    HSK44459

    Drug: HSK44459

Interventions

  • HSK44459 taken orally twice daily in the morning and in the evening for 52weeks.

  • DrugPlacebo

    Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 52 weeks

06

What researchers measure

Primary outcomes

  1. The change from baseline in forced vital capacity (FVC) at week 52

    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness

    Time frame: day 1 and week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Dec 2028, 32 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartEst.
Apr 5, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Mar 1, 2029
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07503587
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Apr 5, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Mar 31, 2026

Study contacts

Sun luyin
Contact
sunluyin@haisco.com
028-67258779

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK44459

Start the discussion